Skip to main content
. 2021 Sep 27;42(4-5):326–334. doi: 10.1177/03331024211046617

Figure 2:

Figure 2:

Absolute changes of monthly migraine days (a), and monthly days with acute medication use (b) compared to baseline during the last mAb treatment month (weeks -4–0) and after treatment discontinuation for all patients, patients with erenumab and patients with galcanezumab/fremanezumab. Values are illustrated as mean ± standard error. ERN = erenumab. GCN/FMN = galcanezumab/fremanezumab. ♦ = significant vs. weeks -4-0. * = significant vs. baseline.